Treace Medical Concepts (NASDAQ:TMCI) Upgraded at Wall Street Zen

Treace Medical Concepts (NASDAQ:TMCI) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other research analysts also recently commented on TMCI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Treace Medical Concepts in a report on Wednesday, January 21st. BTIG Research restated a “neutral” rating on shares of Treace Medical Concepts in a research report on Friday, November 7th. Truist Financial cut their price target on Treace Medical Concepts from $4.00 to $3.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Stifel Nicolaus decreased their price objective on Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating on the stock in a research note on Wednesday, January 7th. Finally, UBS Group dropped their price objective on Treace Medical Concepts from $6.50 to $5.85 and set a “neutral” rating on the stock in a report on Friday, November 7th. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Treace Medical Concepts has a consensus rating of “Reduce” and an average price target of $4.21.

Treace Medical Concepts Stock Performance

Shares of TMCI opened at $2.26 on Friday. The firm has a market cap of $144.01 million, a PE ratio of -2.83 and a beta of 0.74. The stock’s fifty day moving average price is $2.58 and its two-hundred day moving average price is $4.82. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.37 and a quick ratio of 2.36. Treace Medical Concepts has a 1 year low of $2.02 and a 1 year high of $10.45.

Treace Medical Concepts (NASDAQ:TMCI) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. The company had revenue of $50.21 million during the quarter, compared to the consensus estimate of $49.60 million. Treace Medical Concepts had a negative return on equity of 49.49% and a negative net margin of 22.89%. On average, equities research analysts forecast that Treace Medical Concepts will post -0.92 EPS for the current year.

Institutional Trading of Treace Medical Concepts

Several institutional investors and hedge funds have recently modified their holdings of TMCI. Osaic Holdings Inc. grew its holdings in shares of Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after purchasing an additional 3,674 shares in the last quarter. Captrust Financial Advisors purchased a new position in Treace Medical Concepts in the 2nd quarter worth approximately $62,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Treace Medical Concepts in the 3rd quarter worth $87,000. HighTower Advisors LLC purchased a new stake in shares of Treace Medical Concepts during the 4th quarter valued at $33,000. Finally, Invesco Ltd. lifted its holdings in shares of Treace Medical Concepts by 18.6% during the 2nd quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock worth $88,000 after acquiring an additional 2,362 shares during the last quarter. Hedge funds and other institutional investors own 84.08% of the company’s stock.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.